vadastuximab talirine

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Phase 1

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

TerminatedNCT02614560

Seagen Inc.Acute Myeloid Leukemia

Start: 2015-11-30End: 2017-09-14Updated: 2019-01-09

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

TerminatedNCT02706899

Seagen Inc.Myelodysplastic Syndrome

Start: 2016-02-29End: 2017-11-06Updated: 2019-02-12